atrial fibrillation
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients had to have paroxysmal or persistent atrial fibrillation; an absence of response to, unacceptable side effects from, or unwillingness to take antiarrhythmic drugs; and New York Heart Association (NYHA) class II-IV heart failure and a left ventricular ejection fraction (LVEF) of 40% or less.
Exclusion criteria
Exclusion criteria: MI, CABG or PCI within preceding 3 months;Left atrial diameter >50mm; History of heart surgery or any previous ablation for AF; Intracardiac thrombus;Contradictions to anticoagulation; Females who are pregnant or breast feeding; Other severe cardiac dysfunction, cardiac ion channel diseases, inherited arrhythmogenic diseases and so on; Complicated with other severe diseases (e.g. hepatic and renal dysfunction, malignant tumor); Be allergic to iodine contrast medium.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Freedom from AF/AFL/AT recurrences at 12 months following ablation, without antiarrhythmic drug (type I/III) therapy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Freedom from AF/AFL/AT recurrences at 12 months following ablation, with or without antiarrhythmic drug (type I/III) therapy;Proportion of patients with AF/AFL/ATa occurring during the first 90 days post ablation;Trends in NYHA class, LVEF, 6-minute walk distance, and left atrial diameter during follow-up;Quality of life measurements (SF-36); | — |
Countries
China
Contacts
The First Affilated Hospital of Dalian Medical University